Literature DB >> 10102274

Prion protein of 106 residues creates an artifical transmission barrier for prion replication in transgenic mice.

S Supattapone1, P Bosque, T Muramoto, H Wille, C Aagaard, D Peretz, H O Nguyen, C Heinrich, M Torchia, J Safar, F E Cohen, S J DeArmond, S B Prusiner, M Scott.   

Abstract

A redacted prion protein (PrP) of 106 amino acids with two large deletions was expressed in transgenic (Tg) mice deficient for wild-type (wt) PrP (Prnp0/0) and supported prion propagation. RML prions containing full-length PrP(Sc)produced disease in Tg(PrP106)Prnp0/0 mice after approximately 300 days, while transmission of RML106 prions containing PrP(Sc)106 created disease in Tg(PrP106) Prnp0/0 mice after only approximately 66 days on repeated passage. This artificial transmission barrier for the passage of RML prions was diminished by the coexpression of wt MoPrPc in Tg(PrP106)Prnp+/0 mice that developed scrapie in approximately 165 days, suggesting that wt MoPrP acts in trans to accelerate replication of RML106 prions. Purified PrP(Sc)106 was protease resistant, formed filaments, and was insoluble in nondenaturing detergents. The unique features of RML106 prions offer insights into the mechanism of prion replication, and the small size of PrP(Sc)106 should facilitate structural analysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102274     DOI: 10.1016/s0092-8674(00)80596-6

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  60 in total

1.  Cultured cell sublines highly susceptible to prion infection.

Authors:  P J Bosque; S B Prusiner
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein.

Authors:  L Zulianello; K Kaneko; M Scott; S Erpel; D Han; F E Cohen; S B Prusiner
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Affinity-tagged miniprion derivatives spontaneously adopt protease-resistant conformations.

Authors:  S Supattapone; H O Nguyen; T Muramoto; F E Cohen; S J DeArmond; S B Prusiner; M Scott
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 4.  The molecular pathology of CJD: old and new variants.

Authors:  G S Jackson; J Collinge
Journal:  Mol Pathol       Date:  2001-12

5.  Structural studies of the scrapie prion protein by electron crystallography.

Authors:  Holger Wille; Melissa D Michelitsch; Vincent Guenebaut; Surachai Supattapone; Ana Serban; Fred E Cohen; David A Agard; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

6.  Competing intrachain interactions regulate the formation of beta-sheet fibrils in bovine PrP peptides.

Authors:  Abdessamad Tahiri-Alaoui; Mario Bouchard; Jesús Zurdo; William James
Journal:  Protein Sci       Date:  2003-03       Impact factor: 6.725

Review 7.  Transgenesis applied to transmissible spongiform encephalopathies.

Authors:  Jean-Luc Vilotte; Hubert Laude
Journal:  Transgenic Res       Date:  2002-12       Impact factor: 2.788

8.  Evidence for assembly of prions with left-handed beta-helices into trimers.

Authors:  Cédric Govaerts; Holger Wille; Stanley B Prusiner; Fred E Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-21       Impact factor: 11.205

9.  The region approximately between amino acids 81 and 137 of proteinase K-resistant PrPSc is critical for the infectivity of the Chandler prion strain.

Authors:  Ryo Shindoh; Chan-Lan Kim; Chang-Hyun Song; Rie Hasebe; Motohiro Horiuchi
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  Testing the possibility to protect bovine PrPC transgenic Swiss mice against bovine PrPSc infection by DNA vaccination using recombinant plasmid vectors harboring and expressing the complete or partial cDNA sequences of bovine PrPC.

Authors:  Sandra Müller; Roland Kehm; Michaela Handermann; Nurith J Jakob; Udo Bahr; Björn Schröder; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.